Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Pharmacoeconomics. 2023 Nov;41(11):1551. doi: 10.1007/s40273-023-01315-1.

Thomas Otten^{1

2}, Rob Riemsma³, Ben Wijnen^{4

5}, Nigel Armstrong³, Lisa Stirk³, Caroline Gordon³, Bram Ramaekers^{4

6}, Jos Kleijnen³, Manuela Joore^{4

6}, Sabine Grimm⁴

¹ Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+ (MUMC+), P. Debyelaan 25, PO Box 5800, 6202 AZ, Maastricht, The Netherlands. thomas.otten@mumc.nl.
² Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands. thomas.otten@mumc.nl.
³ Kleijnen Systematic Reviews Ltd, York, UK.
⁴ Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+ (MUMC+), P. Debyelaan 25, PO Box 5800, 6202 AZ, Maastricht, The Netherlands.
⁵ Center of Economic Evaluation and Machine Learning, Trimbos Institute (Netherlands Institute of Mental Health and Addiction), Utrecht, The Netherlands.
⁶ Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.

No abstract available

Publication types